Diabetes Imaging Agent
Improve early diagnosis, help monitor disease progression, provide tools to measure responsiveness to therapy and evaluate the efficiency of islet transplantation and graft survival.
Method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. Diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.
D2 receptors (D2R) for dopamine were recently reported on rodent and human islets. University of California researchers propose to use a commercially available ligand with sub-nanomolar affinity and a high degree of specificity for D2R/D3R radiolabeled with fluorine-18 (half-life = 110 minutes) as a positron emission tomography (PET)-scanning agent to quantify changes in β-cell mass associated with diabetes mellitus. The fluorine-18 (18F) radioligand for dopamine D2 receptors (D2R) will be injected into diabetic patients. The radioligand will bind to the D2Rs in islets allowing the radioactive uptake by PET-CT scanning. Loss of beta cells will result in loss of radioligand binding to the pancreas. Since uptake of the radioligand in the liver is low, it may be feasible to detect small changes in the pancreas due to reduced background interference. The use of fluorine-18 as a radiolabel allows the use of the radioligand at facilities that do not have a cyclotron. Furthermore, the ligand is approved for human use making it eminently suitable as a diagnostic tool for T1DM.
Patent Number: US20080319310A1
Application Number: US2008110135A
Inventor: Mukherjee, Jogeshwar | Chandy, George | Milne, Norah | Wang, Ping H. | Easwaramoorthy, Balu | Mantil, Joseph
Priority Date: 26 Apr 2007
Priority Number: US20080319310A1
Application Date: 25 Apr 2008
Publication Date: 25 Dec 2008
IPC Current: A61B0005055
US Class: 600420
Title: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Usefulness: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Summary: The method is useful for monitoring changes in beta cell mass in a patient, where the patient is at preclinical or clinical stage of diabetes such as Type I or Type II diabetes (all claimed).
Novelty: Non-invasive method for monitoring changes in beta cell mass in subject, involves detecting level of dopamine receptor in pancreas of subject
Disease Diagnostic/Treatment
Other Disease
9662059
Tech ID/UC Case 19364/2007-169-0 Related Cases 2007-169-0
USA
